Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA warns topical pain relievers can cause burns; FDA issues another DMAA warning letter; Senators blast FDA’s lack of caffeine concern; Perrigo faces guaifenesin delays; Mead Johnson gets back on track in China.


Related Content

Perrigo CEO Seeks To Check Negative Stock Response
Mead Johnson Upbeat On China Outlook After Series Of Setbacks
DMAA Supplements Banned In U.K., Hamstrung In U.S.
FDA Works To Clarify Supplement/Food Distinction In Durbin Response
Perrigo Launch Investments Hold Income Back, As Firm Girds For 2013
Sales & Earnings In Brief


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts